The Journal of infectious diseases
-
Randomized Controlled Trial Multicenter Study Comparative Study
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
LC16m8 is an attenuated cell culture-adapted Lister vaccinia smallpox vaccine missing the B5R protein and licensed for use in Japan. ⋯ LC16m8 generates neutralizing antibody titers to multiple poxviruses, including vaccinia, monkeypox, and variola major, and broad T-cell responses, indicating that LC16m8 may have efficacy in protecting individuals from smallpox. Clinical Trials Registration. NCT00103584.